Press releasePRNewswire
Intensity Therapeutics
INTS · NASDAQ
$3.28−$0.01 (−0.30%)TodayMarket closed ·
Prev close $3.29
Latest news
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
- Press releasePRNewswire
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
- Press releasePRNewswire
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
- Press releasePRNewswire
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
- Press releasePRNewswire
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
- Press releasePRNewswire
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
- Press releasePRNewswire
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
- Press releasePRNewswire
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
- Press releasePRNewswire
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
- Press releasePRNewswire
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
- NewsNabaparna Bhattacharya
What's Going On With Intensity Therapeutics Stock Friday?
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releasePRNewswire
Intensity Therapeutics Announces Reverse Stock Split
- Press releasePRNewswire
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
- Press releasePRNewswire
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
- Press releasePRNewswire
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
- Press releasePRNewswire
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
Dow Falls Over 100 Points; Amazon Posts Upbeat Q3 Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Apple Earnings Top Views
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
- NewsAvi Kapoor
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
Nasdaq Falls Over 1%; Alphabet Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
- Press releasePRNewswire
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
- Press releasePRNewswire
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
- NewsAvi Kapoor
Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results
- NewsAvi Kapoor
Dow Tumbles Over 100 Points; US Producer Prices Edge Higher In May
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.